Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins).

Presenter

Sai-Hong Ou

Sai-Hong Ignatius Ou, MD, PhD

Chao Family Comprehensive Cancer Center, University of California Irvine

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02716116

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9115)

DOI

10.1200/JCO.2022.40.16_suppl.9115

Abstract #

9115

Poster Bd #

101

Abstract Disclosures

Similar Videos & Slides

Speaker: Anna Rachel Minchom, BCh, MB, MD, MRCP

Speaker: Keunchil Park, MD, PhD

Videos & Slides

2015 ASCO Annual Meeting

Welcome and Introductions

Welcome and Introductions

Speaker: Anthony Cmelak, MD